Goldman Sachs Group Inc Aerie Pharmaceuticals Inc Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	BUY	$6.37 - $15.23 $5.02 Million - $12 Million	788,150 Added 519.68%	939,811 $14.2 Million
Q3 2022 Nov 10, 2022	BUY	$6.37 - $15.23 $5.02 Million - $12 Million	788,150 Added 519.68%	939,811 $14.2 Million
Q2 2022 May 14, 2024	BUY	$4.95 - $9.16 $750,721 - $1.39 Million	151,661 New	151,661 $1.14 Million
Q2 2022 Aug 15, 2022	SELL	$4.95 - $9.16 $602,746 - $1.12 Million	-121,767 Reduced 44.53%	151,661 $1.14 Million
Q1 2022 May 16, 2022	BUY	$5.64 - $9.8 $262,248 - $455,680	46,498 Added 20.49%	273,428 $2.49 Million

Q4 2021 Feb 14, 2022	BUY	$7.02 - $13.33 $86,030 - $163,359	12,255 Added 5.71%	226,930 $1.59 Million
Q3 2021 Nov 10, 2021	BUY	$11.32 - $16.63 $2.43 Million - $3.57 Million	214,675 New	214,675 $2.45 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.